Rapid testing of candidate oncogenes and tumour suppressor genes in signal transduction and neoplastic transformation

Q1 Biochemistry, Genetics and Molecular Biology Advances in biological regulation Pub Date : 2022-01-01 DOI:10.1016/j.jbior.2021.100841
Sha Liu , Paula Medina-Perez , Minh-Cam Ha-Thi , Anja Wieland , Maria Stecklum , Jens Hoffmann , Oleg Tchernitsa , Christine Sers , Reinhold Schäfer
{"title":"Rapid testing of candidate oncogenes and tumour suppressor genes in signal transduction and neoplastic transformation","authors":"Sha Liu ,&nbsp;Paula Medina-Perez ,&nbsp;Minh-Cam Ha-Thi ,&nbsp;Anja Wieland ,&nbsp;Maria Stecklum ,&nbsp;Jens Hoffmann ,&nbsp;Oleg Tchernitsa ,&nbsp;Christine Sers ,&nbsp;Reinhold Schäfer","doi":"10.1016/j.jbior.2021.100841","DOIUrl":null,"url":null,"abstract":"<div><p><span>The COSMIC database (version 94) lists 576 genes in the Cancer Gene Census which have a defined function as drivers of malignancy (oncogenes) or as tumour suppressors<span> (Tier 1). In addition, there are 147 genes with similar functions, but which are less well characterised (Tier 2). Furthermore, next-generation sequencing projects in the context of precision oncology activities are constantly discovering new ones. Since cancer genes differ from their wild-type precursors in numerous molecular and biochemical properties and exert significant differential effects on downstream processes, simple assays that can uncover oncogenic or anti-oncogenic functionality are desirable and may precede more sophisticated analyses. We describe simple functional assays for PTPN11 (protein-tyrosine phosphatase, non-receptor-type 11)/SHP2 mutants, which are typically found in RASopathies and exhibit potential oncogenic activity. We have also designed a functional test for lysyl oxidase<span> (LOX), a prototypical class II tumour suppressor gene whose loss of function may contribute to neoplastic transformation by RAS </span></span></span>oncogenes. Moreover, we applied this test to analyse three co-regulated, RAS-responsive genes for transformation-suppressive activity. The integration of these tests into systems biology studies will contribute to a better understanding of cellular networks in cancer.</p></div>","PeriodicalId":7214,"journal":{"name":"Advances in biological regulation","volume":"83 ","pages":"Article 100841"},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in biological regulation","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2212492621000579","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}
引用次数: 2

Abstract

The COSMIC database (version 94) lists 576 genes in the Cancer Gene Census which have a defined function as drivers of malignancy (oncogenes) or as tumour suppressors (Tier 1). In addition, there are 147 genes with similar functions, but which are less well characterised (Tier 2). Furthermore, next-generation sequencing projects in the context of precision oncology activities are constantly discovering new ones. Since cancer genes differ from their wild-type precursors in numerous molecular and biochemical properties and exert significant differential effects on downstream processes, simple assays that can uncover oncogenic or anti-oncogenic functionality are desirable and may precede more sophisticated analyses. We describe simple functional assays for PTPN11 (protein-tyrosine phosphatase, non-receptor-type 11)/SHP2 mutants, which are typically found in RASopathies and exhibit potential oncogenic activity. We have also designed a functional test for lysyl oxidase (LOX), a prototypical class II tumour suppressor gene whose loss of function may contribute to neoplastic transformation by RAS oncogenes. Moreover, we applied this test to analyse three co-regulated, RAS-responsive genes for transformation-suppressive activity. The integration of these tests into systems biology studies will contribute to a better understanding of cellular networks in cancer.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
在信号转导和肿瘤转化中快速检测候选致癌基因和肿瘤抑制基因。
COSMIC数据库(版本94)在癌症基因普查中列出了576个基因,这些基因具有作为恶性肿瘤驱动因子(癌基因)或肿瘤抑制因子(第1层)的定义功能。此外,还有147个基因具有相似的功能,但特征不太明确(第2层)。此外,在精确肿瘤学活动背景下的下一代测序项目不断发现新的基因。由于癌症基因在许多分子和生化特性上与野生型前体不同,并对下游过程产生显著的差异影响,因此可以发现致癌或抗致癌功能的简单分析是可取的,并且可能先于更复杂的分析。我们描述了PTPN11(蛋白酪氨酸磷酸酶,非受体11型)/SHP2突变体的简单功能分析,这些突变体通常在ras病中发现,并表现出潜在的致癌活性。我们还设计了赖氨酸氧化酶(LOX)的功能测试,赖氨酸氧化酶是一种典型的II类肿瘤抑制基因,其功能的丧失可能有助于RAS癌基因的肿瘤转化。此外,我们应用该测试分析了三个共同调控的ras应答基因的转化抑制活性。将这些测试整合到系统生物学研究中,将有助于更好地了解癌症中的细胞网络。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Advances in biological regulation
Advances in biological regulation Biochemistry, Genetics and Molecular Biology-Molecular Medicine
CiteScore
8.90
自引率
0.00%
发文量
41
审稿时长
17 days
期刊最新文献
Lamins and chromatin join forces. Fructose 1,6-bisphosphatase as a promising target of anticancer treatment. Sphingosine phosphate lyase insufficiency syndrome as a primary immunodeficiency state Expanding functions of the phosphatidylinositol/phosphatidate lipid transporter, PITPNC1 in physiology and in pathology. Hyperactivation of NF-κB signaling in splicing factor mutant myelodysplastic syndromes and therapeutic approaches.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1